赛诺菲
SNY48.470USD
+0.110+0.23%
收盘 12/26, 16:00（美东）报价延迟15分钟
117.99B总市值
11.73市盈率 TTM
关于 赛诺菲 公司
Sanofi SA is a France-based healthcare company based in France. The Company focuses on patient needs and engages in the research, development, manufacture, and marketing of therapeutic solutions. Its three operating segments are: Pharmaceuticals, Consumer Healthcare (CHC), and Vaccines. The Pharmaceuticals includes: Immunology, Multiple Sclerosis / Neurology, Oncology, Rare Diseases, Rare Blood Disorders, Cardiovascular, Diabetes, Established Prescription Products. The Vaccines segment comprises, for all geographical territories, the commercial operations of Sanofi Pasteur, together with research, development, and production activities dedicated to vaccines. The CHC segment comprises the commercial operations for Sanofi’s Consumer Healthcare products, together with research, development and production activities dedicated to those products. The Company’s products developed in collaboration or franchise include Dupixent, Aubagio, Lemtrada, Cerezyme, Lumizyme, Jevtana, Fabrazyme.
赛诺菲简介
公司代码SNY
公司名称Sanofi SA
上市日期Jul 01, 2002
CEOHudson (Paul)
员工数量84587
证券类型Depository Receipt
年结日Jul 01
公司地址46 Avenue de la Grande Armee
城市PARIS
上市交易所NASDAQ OMX - NASDAQ BASIC
国家France
邮编75017
电话33153774000
网址https://www.sanofi.com/
公司代码SNY
上市日期Jul 01, 2002
CEOHudson (Paul)
赛诺菲公司高管
名称
名称/职务
职务
持股
持股变动
Ms. Barbara Lavernos
Ms. Barbara Lavernos
Director
Director
--
--
Dr. Jean-Paul Kress, M.D.
Dr. Jean-Paul Kress, M.D.
Independent Director
Independent Director
--
--
Mr. Emile Voest, M.D., Ph.D.
Mr. Emile Voest, M.D., Ph.D.
Independent Director
Independent Director
--
--
Mr. Olivier Charmeil
Mr. Olivier Charmeil
Executive Vice President - General Medicines, Member of the Executive Committee
Executive Vice President - General Medicines, Member of the Executive Committee
--
--
Dr. Antoine Yver, M.D.
Dr. Antoine Yver, M.D.
Independent Director
Independent Director
--
--
Ms. Julie Van Ongevalle
Ms. Julie Van Ongevalle
Executive Vice President - Consumer Healthcare, Member of the Executive Committee
Executive Vice President - Consumer Healthcare, Member of the Executive Committee
--
--
Ms. Fabienne Lecorvaisier
Ms. Fabienne Lecorvaisier
Independent Director
Independent Director
--
--
Ms. Audrey Duval Derveloy
Ms. Audrey Duval Derveloy
Executive Vice President - Corporate Affairs, Member of the Executive Committee
Executive Vice President - Corporate Affairs, Member of the Executive Committee
--
--
Ms. Clotilde Delbos
Ms. Clotilde Delbos
Independent Director
Independent Director
--
--
Mr. Frederic Oudea
Mr. Frederic Oudea
Independent Chairman of the Board
Independent Chairman of the Board
--
--
查看更多
名称
名称/职务
职务
持股
持股变动
Ms. Barbara Lavernos
Ms. Barbara Lavernos
Director
Director
--
--
Dr. Jean-Paul Kress, M.D.
Dr. Jean-Paul Kress, M.D.
Independent Director
Independent Director
--
--
Mr. Emile Voest, M.D., Ph.D.
Mr. Emile Voest, M.D., Ph.D.
Independent Director
Independent Director
--
--
Mr. Olivier Charmeil
Mr. Olivier Charmeil
Executive Vice President - General Medicines, Member of the Executive Committee
Executive Vice President - General Medicines, Member of the Executive Committee
--
--
Dr. Antoine Yver, M.D.
Dr. Antoine Yver, M.D.
Independent Director
Independent Director
--
--
Ms. Julie Van Ongevalle
Ms. Julie Van Ongevalle
Executive Vice President - Consumer Healthcare, Member of the Executive Committee
Executive Vice President - Consumer Healthcare, Member of the Executive Committee
--
--
收入明细
单位: USD更新时间: 10月6日 周一
单位: USD更新时间: 10月6日 周一
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
FY2018
由于公司未披露，未能获取相关数据
地区USD
名称
营收
占比
United States
5.53B
48.81%
Rest of the World (Japan, South Korea, Canada, Australia, New Zealand)
4.21B
37.18%
Europe
2.38B
21.02%
业务
地区
由于公司未披露，未能获取相关数据
股东统计
更新时间: 11月16日 周日
更新时间: 11月16日 周日
持股股东
股东类型
持股股东
持股股东
占比
Dodge & Cox
2.83%
Fisher Investments
0.52%
Barrow Hanley Global Investors
0.29%
Managed Account Advisors LLC
0.26%
T. Rowe Price Associates, Inc.
0.24%
其他
95.85%
持股股东
持股股东
占比
Dodge & Cox
2.83%
Fisher Investments
0.52%
Barrow Hanley Global Investors
0.29%
Managed Account Advisors LLC
0.26%
T. Rowe Price Associates, Inc.
0.24%
其他
95.85%
股东类型
持股股东
占比
Investment Advisor/Hedge Fund
4.90%
Investment Advisor
3.76%
Research Firm
0.80%
Hedge Fund
0.32%
Bank and Trust
0.07%
Family Office
0.02%
Pension Fund
0.02%
其他
90.11%
机构持股
更新时间: 10月1日 周三
更新时间: 10月1日 周三
报告期
机构数
持股数
持股占比
持股变动
2025Q3
1269
251.34M
10.32%
-27.29M
2025Q2
1261
264.33M
10.86%
-14.23M
2025Q1
1286
268.29M
10.62%
-13.21M
2024Q4
1263
270.44M
10.70%
-30.67M
2024Q3
1239
286.03M
11.43%
-5.72M
2024Q2
1248
275.46M
11.01%
-5.50M
2024Q1
1232
261.25M
10.33%
-7.62M
2023Q4
1213
251.25M
9.93%
-18.33M
2023Q3
1178
256.18M
10.15%
-15.97M
2023Q2
1173
257.65M
10.20%
-26.92M
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
Dodge & Cox
71.72M
2.95%
-1.47M
-2.01%
Jun 30, 2025
Fisher Investments
13.14M
0.54%
-430.96K
-3.18%
Jun 30, 2025
Barrow Hanley Global Investors
7.28M
0.3%
-68.91K
-0.94%
Jun 30, 2025
Managed Account Advisors LLC
7.48M
0.31%
-87.85K
-1.16%
Jun 30, 2025
T. Rowe Price Associates, Inc.
5.52M
0.23%
-5.51M
-49.93%
Jun 30, 2025
Invesco Advisers, Inc.
8.56M
0.35%
-2.81M
-24.69%
Jun 30, 2025
Wellington Management Company, LLP
4.33M
0.18%
-96.41K
-2.18%
Jun 30, 2025
Putnam Investment Management, L.L.C.
4.13M
0.17%
+408.18K
+10.97%
Jun 30, 2025
Boston Partners
3.99M
0.16%
-100.31K
-2.45%
Jun 30, 2025
Mondrian Investment Partners Ltd.
3.44M
0.14%
-10.43K
-0.30%
Mar 31, 2025
查看更多
持股ETF
更新时间: 12月5日 周五
更新时间: 12月5日 周五
机构名称
占比
VanEck Pharmaceutical ETF
10.04%
Invesco International Dividend Achievers ETF
3.05%
Altrius Global Dividend ETF
2.41%
Brandes US Value ETF
2.14%
Putnam Focused Large Cap Value ETF
1.9%
American Century Focused Large Cap Value ETF
1.42%
ProShares Ultra Nasdaq Biotechnology
1.33%
Invesco Nasdaq Biotechnology ETF
1.32%
Invesco ESG NASDAQ Next Gen 100 ETF
0.97%
Invesco NASDAQ Next Gen 100 ETF
0.74%
查看更多
VanEck Pharmaceutical ETF
占比10.04%
Invesco International Dividend Achievers ETF
占比3.05%
Altrius Global Dividend ETF
占比2.41%
Brandes US Value ETF
占比2.14%
Putnam Focused Large Cap Value ETF
占比1.9%
American Century Focused Large Cap Value ETF
占比1.42%
ProShares Ultra Nasdaq Biotechnology
占比1.33%
Invesco Nasdaq Biotechnology ETF
占比1.32%
Invesco ESG NASDAQ Next Gen 100 ETF
占比0.97%
Invesco NASDAQ Next Gen 100 ETF
占比0.74%
分红派息
近5年累计派现
23.51B
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
Apr 15, 2025
SNY.NB Final Cash Dividend of gross USD 2.195331 paid on Jun 12, 2025 going ex on May 09, 2025
May 09, 2025
Jun 12, 2025
May 09, 2025
Mar 26, 2024
SNY.NB Final Cash Dividend of gross USD 2.036908 paid on Jun 06, 2024 going ex on May 09, 2024
May 10, 2024
Jun 06, 2024
May 09, 2024
Feb 15, 2023
SNY.NB Final Cash Dividend of gross USD 1.900085 paid on Jun 23, 2023 going ex on May 30, 2023
May 31, 2023
Jun 23, 2023
May 30, 2023
Apr 20, 2022
SNY.NB Final Cash Dividend of gross USD 1.74684 paid on May 31, 2022 going ex on May 04, 2022
May 05, 2022
May 31, 2022
May 04, 2022
Mar 24, 2021
SNY.NB Final Cash Dividend of gross USD 1.928784 paid on May 26, 2021 going ex on May 03, 2021
May 04, 2021
May 26, 2021
May 03, 2021
Mar 05, 2020
SNY.NB Final Cash Dividend of gross USD 1.699399 paid on May 26, 2020 going ex on Apr 30, 2020
May 01, 2020
May 26, 2020
Apr 30, 2020
拆合股
公告日期
类型
比率
暂无数据
公告日期
类型
比率
暂无数据
常见问题
赛诺菲的前五大股东是谁？
赛诺菲 的前五大股东如下：
Dodge & Cox持有股份：71.72M，占总股份比例：2.95%。
Fisher Investments持有股份：13.14M，占总股份比例：0.54%。
Barrow Hanley Global Investors持有股份：7.28M，占总股份比例：0.30%。
Managed Account Advisors LLC持有股份：7.48M，占总股份比例：0.31%。
T. Rowe Price Associates, Inc.持有股份：5.52M，占总股份比例：0.23%。
Dodge & Cox持有股份：71.72M，占总股份比例：2.95%。
Fisher Investments持有股份：13.14M，占总股份比例：0.54%。
Barrow Hanley Global Investors持有股份：7.28M，占总股份比例：0.30%。
Managed Account Advisors LLC持有股份：7.48M，占总股份比例：0.31%。
T. Rowe Price Associates, Inc.持有股份：5.52M，占总股份比例：0.23%。
赛诺菲的前三大股东类型是什么？
赛诺菲 的前三大股东类型分别是：
Dodge & Cox
Fisher Investments
Barrow Hanley Global Investors
Dodge & Cox
Fisher Investments
Barrow Hanley Global Investors
有多少机构持有赛诺菲(SNY)的股份？
截至2025Q3，共有1269家机构持有赛诺菲的股份，合计持有的股份价值约为251.34M，占公司总股份的10.32%。与2025Q2相比，机构持股有所增加，增幅为-0.53%。
哪个业务部门对赛诺菲的收入贡献最大？
在FY2025Q2，--业务部门对赛诺菲的收入贡献最大，创收--，占总收入的--%。
